Jonathan E Brammer
Overview
Explore the profile of Jonathan E Brammer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
602
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ruiz M, Braunstein Z, McLaughlin E, Mishra A, Porcu P, Brammer J
Haematologica
. 2024 Nov;
PMID: 39540224
Not available.
2.
Maruyama D, Jacobsen E, Porcu P, Allen P, Ishitsuka K, Kusumoto S, et al.
Lancet Oncol
. 2024 Nov;
25(12):1589-1601.
PMID: 39486432
Background: Few treatment options exist for patients with non-Hodgkin lymphoma, and outcomes remain poor for relapsed or refractory disease. We evaluated the safety and preliminary clinical activity of valemetostat, a...
3.
Braunstein Z, Brammer J
Curr Hematol Malig Rep
. 2024 Oct;
19(6):276-284.
PMID: 39425756
Purpose Of Review: Given the poor outcomes for peripheral T-cell lymphomas (PTCL), stem cell transplant (SCT) remains an important therapeutic approach. Post-SCT relapse is common and maintenance therapy post-SCT is...
4.
Goyal A, OLeary D, Dabaja B, Weng W, Zain J, Cutler C, et al.
Transplant Cell Ther
. 2024 Sep;
30(11):1047-1060.
PMID: 39222792
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL). While MF generally follows an indolent course, a subset of patients will experience...
5.
Herrera A, Zain J, Savage K, Feldman T, Brammer J, Chen L, et al.
Lancet Haematol
. 2024 Jul;
11(9):e671-e681.
PMID: 39067464
Background: CD30 expression is universal in anaplastic large-cell lymphoma and is expressed in some other peripheral T-cell lymphoma subtypes. Incorporation of brentuximab vedotin into initial therapy for people with CD30-positive...
6.
Krishan S, Asad Z, Quiroga D, Ghazi S, Quartermaine C, Braunstein Z, et al.
Sci Rep
. 2024 Jul;
14(1):16829.
PMID: 39039091
Hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for several malignant and non-malignant hematologic conditions. However, patients undergoing HSCT are at increased risk of developing serious cardiovascular events....
7.
Bhansali R, Ellin F, Relander T, Cao M, Li W, Long Q, et al.
Blood Adv
. 2024 May;
8(13):3507-3518.
PMID: 38739715
Little is known about risk factors for central nervous system (CNS) relapse in mature T-cell and natural killer cell neoplasms (MTNKNs). We aimed to describe the clinical epidemiology of CNS...
8.
Alhaj Moustafa M, Ramdial J, Tsalatsanis A, Khimani F, Dholaria B, Bojanini L, et al.
Transplant Cell Ther
. 2024 Mar;
30(5):516.e1-516.e10.
PMID: 38431075
Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive type of peripheral T-cell lymphoma with median overall survival (OS) of approximately 1 year. Data on the effectiveness of hematopoietic cell...
9.
Haverkos B, Alpdogan O, Baiocchi R, Brammer J, Feldman T, Capra M, et al.
Blood Adv
. 2023 Aug;
7(20):6339-6350.
PMID: 37530631
Lymphomas are not infrequently associated with the Epstein-Barr virus (EBV), and EBV positivity is linked to worse outcomes in several subtypes. Nanatinostat is a class-I selective oral histone deacetylase inhibitor...
10.
Brammer J, Ballen K, Sokol L, Querfeld C, Nakamura R, Mishra A, et al.
Blood
. 2023 Jun;
142(15):1271-1280.
PMID: 37352612
T-cell large granular lymphocytic leukemia (T-LGLL) is a clonal proliferation of cytotoxic T lymphocytes that can result in severe neutropenia, anemia, and bone marrow failure. Strong evidence from patients and...